Dr. Aderhold hat darauf geantwortet

Hodges, B. (1995): Interactions with the pharmaceutical industry: experiences and attitudes
of
psychiatry residents, interns, and clerks. Canadian Medical Association Journal. 153: 553-
559.
House of Commons Health Committee(2005): The influence of the pharmaceutical industry -
Fourth Report of Session 2004-05
http://www.lindalliance.org/pdfs/HofCHealthCommittee.pdf
Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA.(2006):
Haloperidol dose when used as active comparator in randomized controlled trials with atypical
antipsychotics in schizophrenia: comparison with officially recommended doses.
J Clin Psychiatry. 67(6):897-903.
Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C.(2004): Cognitive behaviour therapy
for schizophrenia. Cochrane Database Syst Rev. (4):CD000524.
Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A,
Lewis SW.(2006) Randomized controlled trial of the effect on Quality of Life of second- vs
first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic
Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 63(10):1079-87.
Joseph KS, Blais L, Ernst P, Suissa S.(1996): Increased morbidity and mortality related to
asthma among asthmatic patients who use major tranquillisers. BMJ. 312(7023):79-82.
Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. (2006): Schizophrenia,
neuroleptic medication and mortality. Br J Psychiatry. 188(2), S. 122-127.
http://bjp.rcpsych.org/cgi/reprint/188/2/122
Khan A, Khan SR, Leventhal RM, Brown WA.(2001) Symptom reduction and suicide risk
among patients treated with placebo in antipsychotic clinical trials: an analysis of the food
and drug administration database. Am J Psychiatry. 158(9):1449-54.
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT.(2008): Initial
severity and antidepressant benefits: a meta-analysis of data submitted to the Food and
Drug Administration. PLoS Med. 5(2):e45.
Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Charles Schulz
S.(2008) Efficacy and tolerability of second-generation antipsychotics in children and adolescents
with schizophrenia. Schizophr Bull. 34(1):60-71.
Lehtinen V.; Aaltonen, J.; Koffert, T. u.a. (2000): Two-year outcome in first episode psychosis
treated according to an integrated model. Is immediate neuroleptisation always needed?
In: European Psychiatry 15: 312-320
Lexchin J, Bero LA, Djulbegovic B, Clark O.(2003): Pharmaceutical industry sponsorship and
research outcome and quality: systematic review. BMJ. 326(7400):1167-70.
Leucht S, Wahlbeck K, Hamann J, Kissling W.(2003): New generation antipsychotics versus
low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet.
361(9369):1581-9.
15